Trial reportNeuropsychiatric disease and treatment2025
Effects of Mobile Neurofeedback on Theta-Gamma Coupling and Clinical Outcomes in Children with ADHD: A Double-Blind, Sham-Controlled Randomized Clinical Trial.
Trial report in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Wireless Electroencephalography in Research on Children With Developmental Disabilities: Scoping Review.Journal of medical Internet research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This double-blinded randomized trial investigated the therapeutic effects of theta/beta mobile neurofeedback (MNF) in 8-15-year-old ADHD and neurotypical children (randomized N = 139; analyzed N = 120). Methods: Participants were divided into three groups: ADHD Combination (MNF + Medication), ADHD MNF alone, and Neurotypical, and each group underwent 3 months of MNF intervention, either active or sham, the latter using randomly generated training results. Pre- and post-intervention electroencephalography tests were conducted, including an analysis of theta-gamma coupling (TGC), along with assessments of clinical variables. Results: Regarding clinical outcomes, MNF was not superior to sham in alleviating ADHD symptoms based on self-reports or in cognitive test performance, as indicated by limited changes in clinical variables. Before the intervention, the Neurotypical group exhibited higher TGC scores than the ADHD groups, reaffirming TGC as a neurophysiological marker for attention and working memory. Post-intervention, the ADHD Combination group with active MNF showed increased TGC in Fp2, F3, F4, F8, P4, O1, and O2, while the ADHD MNF alone group had mixed results. Notably, active MNF had no significant effect on TGC in the Neurotypical group, while sham MNF reduced TGC. Conclusion: MNF produced measurable neurophysiological modulation-reflected in enhanced TGC-when used as an adjunct to medication. Although clinical improvements were modest, these findings support TGC as a sensitive biomarker of MNF-induced brain regulation in ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.